Issue of Warrants

Cambridge Cognition Holdings PLC
05 October 2023
 

5 October 2023

Cambridge Cognition Holdings Plc

 

("Cambridge Cognition", the "Group" or the "Company")

 

Issue of Warrants

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, announces, further to the Company's announcement on 26 September 2023, that the Company has issued Claret European Specialty Lending Company III, S.à r.l. ("Claret") with warrants to subscribe for 722,565 new ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") at an exercise price of 74.734p.

 

Enquiries

 

Cambridge Cognition Holdings Plc  

Matthew Stork, Chief Executive Officer  

Stephen Symonds, Chief Financial Officer 

 

Tel: 012 2381 0700  

press@camcog.com  

Panmure Gordon (UK) Limited (NOMAD and Joint Broker)  

Freddy Crossley / Emma Earl / Mark Rodgers

Rupert Dearden  

 

Tel: 020 7886 2500  

(Corporate Finance)  

(Corporate Broking)  

Dowgate Capital Limited (Joint Broker)  

David Poutney / James Serjeant  

 

Tel: 020 3903 7715  

  

IFC Advisory Ltd (Financial PR and IR)  

Tim Metcalfe / Graham Herring / Zach Cohen  

Tel: 020 3934 6630  

 cog@investor-focus.co.uk

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings